European Multicenter and Open-Label Controlled Randomized Trial to Evaluate the Efficacy of Sequential Treatment With Tacrolimus-Rituximab Versus Steroids Plus Cyclophosphamide in Patients With Primary Membranous Nephropathy (The STARMEN Study)

Trial Profile

European Multicenter and Open-Label Controlled Randomized Trial to Evaluate the Efficacy of Sequential Treatment With Tacrolimus-Rituximab Versus Steroids Plus Cyclophosphamide in Patients With Primary Membranous Nephropathy (The STARMEN Study)

Recruiting
Phase of Trial: Phase III

Latest Information Update: 20 Oct 2016

At a glance

  • Drugs Rituximab (Primary) ; Tacrolimus (Primary) ; Cyclophosphamide; Methylprednisolone; Methylprednisolone
  • Indications Membranous glomerulonephritis
  • Focus Therapeutic Use
  • Acronyms STARMEN
  • Most Recent Events

    • 08 Sep 2015 Planned End Date changed from 1 Jan 2018 to 1 Apr 2019 as reported by ClinicalTrials.gov record.
    • 08 Sep 2015 Planned primary completion date changed from 1 Jul 2017 to 1 Dec 2018 as reported by ClinicalTrials.gov record.
    • 01 Jan 2015 Interim results of 23 subjects enrolled till April 2015 were published in the Clinical Kidney Journal.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top